Get started
Author

William Nathaniel Brennen

Observed names: Brennen, W. N., Brennen, W. Nathaniel, Nathaniel Brennen, W Nathaniel Brennen, W. N. Brennen, W. Nathaniel Brennen, W.N. Brennen, William N. Brennen, W Nathaniel Brennen
Observed institutions: Johns Hopkins University, Pfizer (United States), Lund University, Washington University in St. Louis, Johns Hopkins Medicine, Fred Hutch Cancer Center, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Case Western Reserve University, University of Delaware
ORCID: 0000-0001-9807-7433
Observed ORCID: 0000-0001-9807-7433
OpenAlex ID: A5033192114
Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy
2012 · W. Nathaniel Brennen, John T. Isaacs, et al. · Molecular Cancer Therapeutics · 289
Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise
2018 · Timothy E. G. Krueger, Daniel L. J. Thorek, et al. · Stem Cells Translational Medicine · 242
PDF
Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy
2012 · Samuel R. Denmeade, Annastasiah M. Mhaka, et al. · Science Translational Medicine · 220
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
2010 · Jianqing Lin, Michael C. Haffner, et al. · The Prostate · 194
PDF
Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug
2012 · W. N. Brennen, D. M. Rosen, et al. · JNCI Journal of the National Cancer Institute · 188
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
2009 · Aaron M. LeBeau, W. Nathaniel Brennen, et al. · Molecular Cancer Therapeutics · 159
PDF
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
2012 · John T. Isaacs, Lizamma Antony, et al. · Cancer Research · 116
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors
2020 · Yezi Zhu, Susan L. Dalrymple, et al. · Oncogene · 103
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer
2019 · Michael T. Schweizer, Hao Wang, et al. · Stem Cells Translational Medicine · 96
PDF
Fibroblast Activation Protein Peptide Substrates Identified from Human Collagen I Derived Gelatin Cleavage Sites
2007 · Saurabh Aggarwal, W. Nathaniel Brennen, et al. · Biochemistry · 95
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models
2018 · Nora M. Navone, Wytske M. van Weerden, et al. · The Prostate · 88
PDF
Tumor‐infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
2018 · Timothy E. Krueger, Daniel L. J. Thorek, et al. · The Prostate · 86
Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer
2012 · W. Nathaniel Brennen, Shuangling Chen, et al. · Oncotarget · 84
PDF
Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression
2019 · Robert M. Hughes, Brian W. Simons, et al. · Cancer Research · 75
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer
2016 · Oren Levy, W. Nathaniel Brennen, et al. · Biomaterials · 75
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment
2013 · W Nathaniel Brennen, Samuel R Denmeade, et al. · Endocrine Related Cancer · 71
PDF
IMC-Denoise: a content aware denoising pipeline to enhance Imaging Mass Cytometry
2023 · Peng Lu, Karolyn A. Oetjen, et al. · Nature Communications · 67
PDF
Mesenchymal stem cells and the embryonic reawakening theory of BPH
2018 · W. Nathaniel Brennen, John T. Isaacs · Nature Reviews Urology · 59
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
2021 · W. Nathaniel Brennen, Yezi Zhu, et al. · JCI Insight · 56
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
2022 · Laura A Sena, Rajendra Kumar, et al. · Journal of Clinical Investigation · 46
PDF
Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer
2018 · Binod Kumar, Avi Z. Rosenberg, et al. · Scientific Reports · 46
The Hallmarks of Precancer
2024 · Mary M. Stangis, Zhengyi Chen, et al. · Cancer Discovery · 37
PDF
Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics
2021 · John T. Isaacs, William Nathaniel Brennen, et al. · Molecules · 34
Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype
2022 · Amber E. de Groot, Kayla V. Myers, et al. · Neoplasia · 32
Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy
2020 · W Nathaniel Brennen, Daniel L J Thorek, et al. · Immunotherapy · 32
Works count: 218
Citation count: 3,178
H-index: 29
I10-index: 49
Year
Topic
Type